Self-assembling micelle-like nanoparticles for systemic gene delivery

A nanoparticle and carrier technology, applied in the field of self-assembled micelle-like nanoparticles for gene delivery in vivo, can solve the problems of complex and time-consuming preparation steps, low carrying capacity, long circulation time, etc., and achieve a repeatable preparation method, The effect of high load-carrying capacity
CN101970687AInactive Publication Date: 2011-02-09NORTHEASTERN UNIV LIAONING
8 Cites 21 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NORTHEASTERN UNIV LIAONING
Publication Date
2011-02-09
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

Nanoparticles containing nucleic acid and suitable for use as in vivo delivery agents for nucleic acids are provided. The nanoparticles use a covalent conjugate of a polycation such as polyethylenimine and phospholipids. The final DNA- containing nanoparticle has a vesicular structure with a polyplex core surrounded by a mixed lipid / PEG- lipid monolayer envelope and offers simple preparation, high loading capacity, and in vivo stability. The nanoparticles have good in vivo stability and a prolonged blood circulation time and can effectively deliver a gene to a biological target such as a tumor.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross References to Related Applications

[0002] This application claims priority to US Provisional Application No. 61 / 002,626, filed November 9, 2007, entitled Gene Delivery Nanoparticles, which is incorporated herein by reference in its entirety.

[0003] Statement Regarding Federal Funding for Research or Development

[0004] Research on the present invention was performed with US Government support using National Institutes of Health grant No. R01HL55519. Accordingly, the US Government has certain rights in this invention. Background of the invention

[0005] In vivo gene therapy relies on the delivery of DNA-based drugs, either in the form of oligonucleotides (antisense oligodeoxynucleotide (ODN) siRNA) or entire genes (plasmid DNA) into cells where they function. Location. With few exceptions where it can be administered locally, widespread clinical application of gene therapy will require the development of non-invasive delivery methods. A non-viral system i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More